论文部分内容阅读
目的探讨经导管肝动脉化疗栓塞(TACE)联合康莱特注射液治疗原发性肝癌的临床疗效。方法 90例原发性肝癌患者随机分成3组,每组各30例。A组采用TACE联合康莱特注射液动静脉注射;B组行TACE及康莱特注射液静注;C组单纯行TACE。结果 TACE联合康莱特注射液动静脉注射治疗原发性肝癌,其实体瘤疗效、生存期均优于单纯TACE及TACE联合康莱特注射液静脉注射组,但三者之间差异无显著性(P>0.05);B组及A组患者生存质量优于C组,差异有显著性(P<0.05),但A、B两组之间差异无显著性(P>0.05)。未见明显的毒副作用。结论 TACE联合康莱特注射液动静脉注射治疗原发性肝癌可减小瘤体体积,改善临床症状,改善患者生活质量,且毒副反应小,安全可行。
Objective To investigate the clinical efficacy of transcatheter hepatic arterial chemoembolization (TACE) and Kanglaite injection in the treatment of primary liver cancer. Methods 90 patients with primary liver cancer were randomly divided into 3 groups, each group 30 cases. Group A was given TACE combined with KLT injection; group B received TACE and Kanglaite injection; Group C was treated with TACE alone. Results TACE combined with Kanglaite injection of arteriovenous injection for the treatment of primary liver cancer, its solid tumor efficacy and survival were better than pure TACE and TACE combined Kanglaite injection intravenous injection group, but the difference between the three was not significant (P > 0.05). The quality of life of patients in group B and group A was better than that of group C (P <0.05), but there was no significant difference between group A and group B (P> 0.05). No obvious side effects. Conclusion TACE combined with Kanglaite injection of arteriovenous injection for the treatment of primary liver cancer can reduce the tumor volume, improve clinical symptoms, improve the quality of life of patients, and the side effects of small, safe and feasible.